Skip to main content
. Author manuscript; available in PMC: 2020 Sep 25.
Published in final edited form as: Nat Med. 2019 Apr 22;25(6):947–953. doi: 10.1038/s41591-019-0421-7

Fig. 2 |. Patients with refractory or relapsed lymphoma achieved durable remission after CD19-BBz(86) CAR T cell treatment.

Fig. 2 |

a, Representative PET–CT scans of six patients before and after CAR T cell treatment showing durable complete remission. Red arrows indicate sites of lymphoma. Top, PET–CT scans taken before CAR T cell therapy; middle, PET–CT scans taken approximately 1 month after (days 27–35) CAR T cell therapy; bottom, PET–CT scans at the most recent follow-up (day 237 for patient BZ015, day 242 for patient BZ016, day 209 for patient BZ019, day 129 for patient BZ020, day 203 for patient BZ021 and day 119 for patient BZ025). Scale bars, 10 cm. b, CT scans showing long-term remission in patient BZ004 treated with CD19-BBz(86) CAR T cells at a dose of 3 × 106 cells. Circles indicate sites of lymphoma. Scale bars, 10 cm. c, Treatment response of each patient after CD19-BBz(86) CAR T cell treatment and the duration of response. Ongoing remission is marked by a black arrow. Patient number and dose of CD19-BBz(86) CAR T cells are shown to the left of the y axis. CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.